China Universal Asset Management Co., Ltd. Bellus Health Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 21, 2024	SELL	$0.0 - $14.75 $0 - $1,047	-71 Reduced 4.16%	1,634 $0
Q2 2023 Jul 27, 2023	SELL	$0.0 - $14.75 $0 - $1,047	-71 Reduced 4.16%	1,634 $24,000
Q1 2023 May 21, 2024	BUY	$7.14 - $8.53 $3,055 - $3,650	428 Added 33.52%	1,705 $12,000
Q1 2023 Apr 27, 2023	BUY	$7.14 - $8.53 $3,055 - $3,650	428 Added 33.52%	1,705 $12,000
Q4 2022 May 21, 2024	BUY	$8.22 - $10.76 $10,496 - $13,740	1,277 New	1,277 $10,000
Q4 2022 Jan 31, 2023	BUY	$8.22 - $10.76 $813 - $1,065	99 Added 8.4%	1,277 $10,000
Q3 2022 Oct 21, 2022	BUY	$8.95 - $12.0 $10,543 - $14,136	1,178 New	1,178 $12,000

Others Institutions Holding BLU

# of Institutions

Shares Held

128K

Call Options Held

Put Options Held

Pendal Group LTD

128K
Shares

$0
0.01% of portfolio

View Full List

About BELLUS Health Inc.

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

More about BLU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account